menu search

Perspective Therapeutics Reports First Quarter Fiscal 2023 Results

Perspective Therapeutics Reports First Quarter Fiscal 2023 Results
Additional CDMO capabilities added to increase availability of clinical trial product in the US Phase I/IIa studies are initiating in the first half of 2023 for VMT-α-NET for neuroendocrine tumors and VMT-01 for melanoma RICHLAND, WASHINGTON & CORALVILLE, IOWA, May 15, 2023 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a precision oncology company […] The post Perspective Therapeutics Reports First Quarter Fiscal 2023 Results appeared first on ForexTV... Read More
Posted: May 16 2023, 00:22
Author Name: forextv
Views: 081599

Search within

Pages Search Results: